Web of Science (Emerging Sources Citation Index), Scopus, ISC

Document Type : Original Research Article

Authors

1 Assistant Professor of Cardiology, Department of Cardiology, School of Medicine, Shahid Mostafa Khomaeini Hospital, Ilam University of Medical sciences, Ilam, Iran

2 School of Medicine, Shahid Mostafa Khomaeini Hospital, Ilam University of Medical Sciences, Ilam, Iran

3 Instructor of Medical Surgical Nursing, Department of Anesthesiology, School of Allied Medical Sciences, Ilam University of Medical Sciences, Ilam, Iran

4 Shahid Mostafa Khomaeini Hospital, Ilam University of Medical Sciences, Ilam, Iran

Abstract

Pharmacotherapy is one of the most important measures for improving the health status of patients, which can play a key role in this regard. The present study was performed to compare the effect of atorvastatin plus rosuvastatin on the value of laboratory markers in CVD patients. This research is a clinical trial study, whose research population consisted of the patients with ACS in Ilam city in 2021. The patients were randomly assigned into three groups: control, intervention A (receiving atorvastatin), and intervention B (receiving rosuvastatin). The patients who met the inclusion criteria were enrolled in the study through available sampling, for all of whom the required tests were performed. The laboratory variables including tests of triglyceride, cholesterol, ALT, AST, ALP, LDH, and LDL, using a single device which was in the laboratory in Ilam city were completed and the documents related to them were considered as assessment criteria. The data analysis was done using SPSS 16 software. The table indicated the comparison of laboratory index scores before and after taking rosuvastatin. According to the findings, in all laboratory indices after taking rosuvastatin, the status of the index has changed significantly to improve the patient’s health status (p <0.05). Considering the greater effect of rosuvastatin compared to atorvastatin on improving the laboratory variables, prescription of this drug is suggested for improving the status of CVD patients.

Graphical Abstract

Comparing the effect of drugs atorvastatin and rosuvastatin on the level of laboratory markers acute coronary syndrome patients

Keywords

Main Subjects

[1] E. Nasiri, R. Gazor, S. Sayad Fathi, J. Babol Univ. Medical Sci., 2018, 20, 71-75. [Crossref], [Google Scholar], [Publisher]
[2] Z. Khodadad Hatkeh Poshti, R. Hassanzadeh, S. Emadian, J. Babol Univ. Medical Sci., 2021, 23, 46-52. [Crossref], [Google Scholar], [Publisher]
[3] C.R. Pischke, G. Weidner, M. Elliott-Eller, L. Scherwitz, T.A. Merritt-Worden, R. Marlin, L. Lipsenthal, R. Finkel, D. Saunders, P. Mc Cormac, M. Scheer, R.E. Collins, E.M. Guarneri, D. Ornish, Am. J. Cardiol., 2006, 97, 1267-1273. [Crossref], [Google Scholar], [Publisher]
[4] M.T. Salehi omran, M. Sadeghpour, A.A. Yaghoubi, R. Shamsi, J. Babol Univ. Medical Sci., 2017, 19, 7-14. [Crossref], [Google Scholar], [Publisher]
[5] U. Ralapanawa, R.J.J.o.E. Sivakanesan, G. Health, J Epidemiol Glob Health, 2021, 11, 169, [Crossref], [Google Scholar], [Publisher]
[6] D. Takahashi, H. Wada, M. Ogita, K. Yasuda, R. Nishio, M. Takeuchi, N. Takahashi, S. Yatsu, T. Sonoda, J. Shitara, S. Suwa, T. Dohi, K. Miyauchi, H. Daida, T. Minamino, Am. J. Cardiol., 2022, 168, 11-16. [Crossref], [Google Scholar], [Publisher]
[7] F. Najafi, Z. Pishkar Mofrad, E. Ayubi, R. Hosseini, HAYAT, 2020, 26, 455-468. [Crossref], [Google Scholar], [Publisher]
[8] O. Berwanger, et al., Jama, 2018, 319, 1331-1340. [Crossref], [Google Scholar], [Publisher]
[9] N. Sorathia, H. Al-Rubaye, B.J.E.C.R. Zal, Eur Cardiol, 2019, 14, 123. [Crossref], [Google Scholar], [Publisher]
[10] M. Ma, L. Bu, L. Shi, R. Guo, B. Yang, H. Cao, L. Luo, L. Lu, Drug Des Devel Ther., 2019, 13, 1233. [Crossref], [Google Scholar], [Publisher]
[11] M.C. Serban, L.D. Colantonio, A.D. Manthripragada, K.L. Monda, V.A. Bittner, M. Banach, L. Chen, L. Huang, R. Dent, S.T. Kent, P. Muntner, R.S. Rosenson, J. Am. Coll. Cardiol.‎, 2017, 69, 1386-1395. [Crossref], [Google Scholar], [Publisher]
[12] Q. Chen, X. Shang, M. Yuan, L. Liang, X. Zhong, Coronary Artery Disease, 2017, 28, 44-51. [Crossref], [Google Scholar], [Publisher]
[13] D.E. Nixon, R.J. Bosch, E.S. Chan, N.T. Funderburg, S. Hodder, J.E. Lake, M.M. Lederman, K.L. Klingman, J.A. Aberg, J. Clin. Lipidol., 2017, 11, 61-69. [Crossref], [Google Scholar], [Publisher]
[14] S.H. Aghamiri, K. Komlakh, M. Ghaffari, Inflammopharmacol, 2022, 30, 51–60. [Crossref], [Google Scholar], [Publisher]
[15] A. Abdi, A. Soufinia, M. Borji, A. Tarjoman, J Relig Health, 2019, 58, 823–832. [Crossref], [Google Scholar], [Publisher]
[16] S.H. Aghamiri, K. Komlakh, M. Ghaffari, Int. Immunopharmacol., 2022, 102, 108398. [Crossref], [Google Scholar], [Publisher]
[17] M. Borji, M. Otaghi, E. Salimi, P. Sanei, Biomed Res, 2017, 28, 7076-7080. [Crossref], [Google Scholar], [Publisher]
[18] Y. Ji, T. Rounds, A. Crocker, B. Sussman, R.C. Hovey, F. Kingsley, H.B. Muss, J.E. Garber, M.E. Wood, Cancer Prev. Res., 2016, 9, 379-384. [Crossref], [Google Scholar], [Publisher]
[20] R.G. Fassett, et al., Clin. Nephrol., 2014. 81, 75-85. [Crossref], [Google Scholar], [Pdf]
[21] T.R. Sexton, E.L. Wallace, T.E. Macaulay, R.J. Charnigo, V. Evangelista, C.L. Campbell, A.L. Bailey, S.S. Smyth, J. Thromb. Thrombolysis‎, 2015, 39, 186-195,. [Crossref], [Google Scholar], [Publisher]
[22] R. Luo, X. Sun, F. Shen, B. Hong, Z. Wang, Drug Des Devel Ther., 2020, 14, 3891-3898, [Crossref], [Google Scholar], [Publisher]
[23] A.C. Hearps, T.A. Angelovich, J.M. Trevillyan, M.E. Wong, A. Calmy, J.F. Hoy, A. Jaworowski, J. Infect. Dis., 2021, 224, 667-672. [Crossref], [Google Scholar], [Publisher]
[24] S. Umrani, W. Jamshed, A.J.C. Rizwan, Cureus., 2020, 12, e11760 [Crossref], [Google Scholar], [Publisher]
[25] I.G.A.I.H. Pratiwi, A.A.G.W. Putra, Intisari Sains Medis, 13, 121-126. [Crossref], [Google Scholar], [Publisher]
[26] B. Kumar, M. A. Asghar Shah, R. Kumar, J. Kumar, A. Memon, Cureus, 2019, 11, e4898. [Crossref], [Google Scholar], [Publisher]